CRSP Q2 EPS Increased by Brookline Capital Acquisition

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Brookline Capital Acquisition increased their Q2 2026 EPS estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, March 11th. Brookline Capital Acquisition analyst L. Cann now forecasts that the company will post earnings per share of ($1.16) for the quarter, up from their previous forecast of ($1.22). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Acquisition also issued estimates for CRISPR Therapeutics’ Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($4.96) EPS and FY2027 earnings at ($5.51) EPS.

CRSP has been the subject of several other reports. Bank of America decreased their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Citizens Jmp decreased their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Chardan Capital upped their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Finally, Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Price Performance

CRSP stock opened at $48.87 on Friday. The stock has a market capitalization of $4.69 billion, a P/E ratio of -7.50 and a beta of 1.72. The business has a fifty day moving average price of $54.20 and a 200-day moving average price of $57.28. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $4.72 million. During the same quarter in the previous year, the firm posted ($1.01) earnings per share. The firm’s revenue for the quarter was down 97.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc grew its holdings in shares of CRISPR Therapeutics by 59.7% during the 2nd quarter. Legal & General Group Plc now owns 129,567 shares of the company’s stock worth $6,302,000 after purchasing an additional 48,412 shares during the period. Philadelphia Trust Co. bought a new position in CRISPR Therapeutics during the 2nd quarter valued at approximately $2,444,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of CRISPR Therapeutics in the second quarter worth approximately $911,000. JPMorgan Chase & Co. grew its position in CRISPR Therapeutics by 98.3% in the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after acquiring an additional 294,222 shares during the period. Finally, Nwam LLC increased its stake in CRISPR Therapeutics by 455.7% in the third quarter. Nwam LLC now owns 101,769 shares of the company’s stock valued at $6,770,000 after purchasing an additional 83,454 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the sale, the chief executive officer directly owned 134,201 shares in the company, valued at $8,082,926.23. This trade represents a 30.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,800 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total transaction of $147,840.00. Following the completion of the transaction, the general counsel directly owned 87,815 shares of the company’s stock, valued at $4,636,632. This trade represents a 3.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 111,677 shares of company stock valued at $6,308,848. 4.30% of the stock is owned by insiders.

Key Headlines Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY2025 commercial progress — CASGEVY generated meaningful revenue ($116M for FY25, $54M in Q4), showing commercial traction that supports long-term upside. Article Title
• Positive Sentiment: Analyst small upgrades — Brookline slightly raised Q2 2026 and FY2026 EPS forecasts (Q2 to -$1.16; FY2026 to -$4.96) and modestly raised FY2027, a sign one sell-side shop sees marginally better near-term results (still negative EPS).
• Neutral Sentiment: High-profile trading headlines — reports that ARK Invest was buying CRSP while the stock moved sharply have drawn attention and increased volatility; buying by a marquee investor can support sentiment but also coincides with short-term swings. Article Title
• Neutral Sentiment: Short-interest reporting appears anomalous/blank in recent feeds (zeros/NaN), so retail/quant signals from short data are unclear and likely not driving a clear directional signal.
• Negative Sentiment: $550M convertible senior notes offering — CRISPR priced an upsized $550M convertible debt offering due 2031. This raises cash (runway) but creates potential share dilution if converted and tends to weigh on equity sentiment near-term. Article Title
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni sold ~9,798 shares and General Counsel James Kasinger sold ~2,800 shares at ~$52.80. Insider sales can be interpreted negatively by some investors even if for personal liquidity; filings: CEO SEC Filing and GC SEC Filing
• Negative Sentiment: Mixed-to-lower estimate tweaks for some quarters and out years — Brookline trimmed Q3/Q4 2026 and reduced FY2028–FY2030 estimates slightly, signaling continued uncertainty around timing of profitability and long-term modeling.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.